These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 36574905)

  • 1. The race toward a universal influenza vaccine: Front runners and the future directions.
    Hu L; Lao G; Liu R; Feng J; Long F; Peng T
    Antiviral Res; 2023 Feb; 210():105505. PubMed ID: 36574905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthetic Toll-like receptor 4 (TLR4) and TLR7 ligands as influenza virus vaccine adjuvants induce rapid, sustained, and broadly protective responses.
    Goff PH; Hayashi T; Martínez-Gil L; Corr M; Crain B; Yao S; Cottam HB; Chan M; Ramos I; Eggink D; Heshmati M; Krammer F; Messer K; Pu M; Fernandez-Sesma A; Palese P; Carson DA
    J Virol; 2015 Mar; 89(6):3221-35. PubMed ID: 25568203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Next-Generation Influenza HA Immunogens and Adjuvants in Pursuit of a Broadly Protective Vaccine.
    Nagashima KA; Mousa JJ
    Viruses; 2021 Mar; 13(4):. PubMed ID: 33805245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elicitation of Protective Antibodies against 20 Years of Future H3N2 Cocirculating Influenza Virus Variants in Ferrets Preimmune to Historical H3N2 Influenza Viruses.
    Allen JD; Jang H; DiNapoli J; Kleanthous H; Ross TM
    J Virol; 2019 Feb; 93(3):. PubMed ID: 30429350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutations in the Hemagglutinin Stalk Domain Do Not Permit Escape from a Protective, Stalk-Based Vaccine-Induced Immune Response in the Mouse Model.
    Roubidoux EK; Carreño JM; McMahon M; Jiang K; van Bakel H; Wilson P; Krammer F
    mBio; 2021 Feb; 12(1):. PubMed ID: 33593972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting Antigens for Universal Influenza Vaccine Development.
    Nguyen QT; Choi YK
    Viruses; 2021 May; 13(6):. PubMed ID: 34073996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progress towards the Development of a Universal Influenza Vaccine.
    Wang WC; Sayedahmed EE; Sambhara S; Mittal SK
    Viruses; 2022 Jul; 14(8):. PubMed ID: 36016306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Universal influenza vaccines: Shifting to better vaccines.
    Berlanda Scorza F; Tsvetnitsky V; Donnelly JJ
    Vaccine; 2016 Jun; 34(26):2926-2933. PubMed ID: 27038130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cross-Protection by Inactivated H5 Prepandemic Vaccine Seed Strains against Diverse Goose/Guangdong Lineage H5N1 Highly Pathogenic Avian Influenza Viruses.
    Criado MF; Sá E Silva M; Lee DH; Salge CAL; Spackman E; Donis R; Wan XF; Swayne DE
    J Virol; 2020 Nov; 94(24):. PubMed ID: 32999029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Towards a universal influenza vaccine: different approaches for one goal.
    Sautto GA; Kirchenbaum GA; Ross TM
    Virol J; 2018 Jan; 15(1):17. PubMed ID: 29370862
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Broadly Protective CD8
    Zhang H; Zheng H; Guo P; Hu L; Wang Z; Wang J; Ju Y; Meng S
    J Virol; 2021 May; 95(12):. PubMed ID: 33827939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Universal Influenza Vaccine Approaches Using Full-Length or Head-Only Hemagglutinin Proteins.
    Ross TM
    J Infect Dis; 2019 Apr; 219(Suppl_1):S57-S61. PubMed ID: 30715379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Computationally Optimized Broadly Reactive Hemagglutinin Elicits Hemagglutination Inhibition Antibodies against a Panel of H3N2 Influenza Virus Cocirculating Variants.
    Wong TM; Allen JD; Bebin-Blackwell AG; Carter DM; Alefantis T; DiNapoli J; Kleanthous H; Ross TM
    J Virol; 2017 Dec; 91(24):. PubMed ID: 28978710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Bivalent Heterologous DNA Virus-Like-Particle Prime-Boost Vaccine Elicits Broad Protection against both Group 1 and 2 Influenza A Viruses.
    Jiang W; Wang S; Chen H; Ren H; Huang X; Wang G; Chen Z; Chen L; Chen Z; Zhou P
    J Virol; 2017 May; 91(9):. PubMed ID: 28179535
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of broadly reactive influenza vaccines by targeting the conserved regions of the hemagglutinin stem and head domains.
    De Jong NMC; Aartse A; Van Gils MJ; Eggink D
    Expert Rev Vaccines; 2020 Jun; 19(6):563-577. PubMed ID: 32510256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conformational Stability of the Hemagglutinin of H5N1 Influenza A Viruses Influences Susceptibility to Broadly Neutralizing Stem Antibodies.
    Wang W; Song HS; Keller PW; Alvarado-Facundo E; Vassell R; Weiss CD
    J Virol; 2018 Jun; 92(12):. PubMed ID: 29593038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Strategies towards universal pandemic influenza vaccines.
    He F; Leyrer S; Kwang J
    Expert Rev Vaccines; 2016; 15(2):215-25. PubMed ID: 26641724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting Hemagglutinin: Approaches for Broad Protection against the Influenza A Virus.
    Zhang Y; Xu C; Zhang H; Liu GD; Xue C; Cao Y
    Viruses; 2019 Apr; 11(5):. PubMed ID: 31052339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Universal influenza vaccines, science fiction or soon reality?
    de Vries RD; Altenburg AF; Rimmelzwaan GF
    Expert Rev Vaccines; 2015; 14(10):1299-301. PubMed ID: 26104835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influenza Virus Hemagglutinin Stalk-Specific Antibodies in Human Serum are a Surrogate Marker for
    Jacobsen H; Rajendran M; Choi A; Sjursen H; Brokstad KA; Cox RJ; Palese P; Krammer F; Nachbagauer R
    mBio; 2017 Sep; 8(5):. PubMed ID: 28928215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.